Viatris is launching the first commercially available, FDA-approved eyedrop for the reversal of dilation, according to a press release.
The FDA approved Ryzumvi (phentolamine ophthalmic solution 0.75%) in September 2023 following positive results of two randomized, vehicle-controlled trials.
In the MIRA-2 and MIRA-3 trials, 553 patients aged 12 to 80 years underwent mydriasisinduced by instillation of phenylephrine, tropicamide or Paremyd (hydroxyamphetamine hydrobromide/tropicamide ophthalmic solution) followed by two drops of Ryzumvi in the study eye or one drop in the fellow eye of either